Cinvanti Approved to Prevent Chemotherapy-Induced Nausea
November 9, 2017 – The U.S. FDA has approved Cinvanti™ (aprepitant) injectable emulsion, manufactured by Heron Therapeutics, as an antiemetic to prevent chemotherapy-induced nausea and vomiting (CINV) in adult patients who are receiving treatment with chemo drugs that present a moderate or high risk of CINV. Administered as an intravenous infusion, Cinvanti is to be used in conjunction with a corticosteroid and a serotonin-3 (5-HT3) receptor inhibitor, such as ondansetron.
Cinvanti is a substance P/neurokinin-1 (NK1) receptor antagonist. This type of drug works by blocking certain receptor sites in the brain. Cinvanti can be used to prevent both acute and delayed episodes of CINV. Recommended dosing is 130mg if the chemo drugs being used are associated with a high risk of CINV, and 100mg for drugs that present only a moderate risk. In both cases, Cinvanti is administered as a 30-minute infusion approximately half an hour before the administration of chemotherapy.
Launch of the drug is expected in January 2018.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- U.S. Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.